Treatment results of alternating chemoradiotherapy followed by proton beam therapy boost combined with intra-arterial infusion chemotherapy for stage III–IVB tongue cancer

Takayama, Kohei; Nakamura, Tatsuya; Takada, Akinori; Makita, Chiyoko; Suzuki, Motohisa; Azami, Yusuke; Katō, Takahiro; Hayashi, Yuichiro; Ono, Takashi; Toyomasu, Yutaka; Hareyama, Masato; Kikuchi, Yasuhiro; Daimon, Takashi; Mitsudo, Kenji; Tohnai, Iwai; Fuwa, Nobukazu

doi:10.1007/s00432-015-2069-0

Cited by 33 publications

(39 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second, this is the first study to report the planned sequential combination HT and IMPT. In previous studies, PBT was mainly used as a boost technique following or simultaneously with photon therapy, and also showed favorable toxicity and treatment results. Third, the acute toxicity profiles were, more or less, favorable following the HT/IMPT combination, while oncologic outcomes were all excellent and comparable.…”

Section: Discussionmentioning

confidence: 99%

Early clinical outcomes of helical tomotherapy/intensity‐modulated proton therapy combination in nasopharynx cancer

Park

Ahn

et al. 2019

Cancer Science

View full text Add to dashboard Cite

This study aimed to evaluate the feasibility of combining helical tomotherapy (HT) and intensity‐modulated proton therapy (IMPT) in treating patients with nasopharynx cancer (NPC). From January 2016 to March 2018, 98 patients received definitive radiation therapy (RT) with concurrent chemotherapy (CCRT). Using simultaneous integrated boost and adaptive re‐plan, 3 different dose levels were prescribed: 68.4 Gy in 30 parts to gross tumor volume (GTV), 60 Gy in 30 parts to high‐risk clinical target volume (CTV), and 36 Gy in 18 parts to low‐risk CTV. In all patients, the initial 18 fractions were delivered by HT, and, after rival plan evaluation on the adaptive re‐plan, the later 12 fractions were delivered either by HT in 63 patients (64.3%, HT only) or IMPT in 35 patients (35.7%, HT/IMPT combination), respectively. Propensity‐score matching was conducted to control differences in patient characteristics. In all patients, grade ≥ 2 mucositis (69.8% vs 45.7%, P = .019) and grade ≥ 2 analgesic usage (54% vs 37.1%, P = .110) were found to be less frequent in HT/IMPT group. In matched patients, grade ≥ 2 mucositis were still less frequent numerically in HT/IMPT group (62.9% vs 45.7%, P = .150). In univariate analysis, stage IV disease and larger GTV volume were associated with increased grade ≥ 2 mucositis. There was no significant factor in multivariate analysis. With the median 14 month follow‐up, locoregional and distant failures occurred in 9 (9.2%) and 12 (12.2%) patients without difference by RT modality. In conclusion, comparable early oncologic outcomes with more favorable acute toxicity profiles were achievable by HT/IMPT combination in treating NPC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Early clinical outcomes of helical tomotherapy/intensity‐modulated proton therapy combination in nasopharynx cancer

Park

Ahn

et al. 2019

Cancer Science

View full text Add to dashboard Cite

show abstract

“…In general, the incidence of ORN post RT or intensity-modulated radiotherapy (IMRT) was reported to range from 2% to 16% [29, 30]. Takayama et al [31] reported good treatment outcomes of PBT combined with intra-arterial chemotherapy for T3–4 tongue cancer (3-year OS of 87%). They also reported that, by using a spacer to fix the tongue and to avoid extra irradiation to the mandible, the incidence of ORN was only 3% (1 of 33 patients).…”

Section: Discussionmentioning

confidence: 99%

Clinical outcomes of retrograde intra-arterial chemotherapy concurrent with radiotherapy for elderly oral squamous cell carcinoma patients aged over 80 years old

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundThe aim of this retrospective observational study was to evaluate toxicities, overall survival, and locoregional control in elderly oral squamous cell carcinoma patients who had undergone retrograde intra-arterial chemotherapy combined with radiotherapy.MethodsThirty-one elderly patients over 80 years old with oral squamous cell carcinoma were enrolled in present study. The treatment schedule consisted of intra- arterial chemotherapy (docetaxel, total 60 mg/m2; cisplatin, total 150 mg/m2) and daily concurrent radiotherapy (total, 60 Gy) for 6 weeks.ResultsThe median patient age was 82.5 years old (range, 80–88 years). Of the 31 patients, six (19%) had stage II, 6 (19%) had stage III, 17 (55%) had stage IVA, and 2 (6%) had stage IVB. The median follow-up period for all patients was 37 months (range, 7–86 months). The 3-year overall survival and locoregional control rates were 78% and 81%, respectively. The major acute grade 3 adverse events were oral mucositis in 22 (71%) patients, neutropenia in 16 (52%), and dermatitis in 11 (35%). With respect to late toxicities, 1 patient (3%) developed grade 3 osteoradionecrosis of the jaw. No grade 4 or higher toxicities were observed during the treatment and follow-up periods.ConclusionsRetrograde intra-arterial chemotherapy combined with radiotherapy was effective in improving overall survival and locoregional control even for elderly patients.

show abstract

“…Огромную роль в лечении местнораспространённого плоскоклеточного рака полости рта играет сочетание внутриартериальной полихимиотерапии по методу Сельдингера и ретроградной суперселективной внутриартериальной полихимиотерапии в комбинации с лучевой терапией [12,13]. Существует два типа суперселективной внутриартериальной катетеризации: антеградная и ретроградная катетеризация.…”

Section: материалы и методыunclassified

“…В этом методе катетер вводился в целевую артерию через поверхностную височную артерию (STA) и / или затылочную артерию (ОА) ретроградно, при этом катетеры сохранялись до завершения лечения. Таким образом, метод HFT позволяет проводить ежедневную химиолучевую терапию [12,13].…”

Section: материалы и методыunclassified

Современные Аспекты Лечения Плоскоклеточного Рака Головы И шеи

Седаков¹,

Семикоз²,

Комендант³

et al. 2018

View full text Add to dashboard Cite

Цель: изучить современные подходы, результаты лечения больных с плоскоклеточным раком головы и шеи. Материалы и методы: Большинство пациентов с плоскоклеточным раком головы и шеи имеют на момент обращения местнораспространенный опухолевый процесс. Первоначально была принята тактика комбинированного лечения с предоперационным облучением. В 1999 г. были опубликованы результаты рандомизированного исследования RTOG 73–03, убедительно продемонстрировавшего преимущества послеоперационного облучения над дооперационным. Пациенты с плоскоклеточным раком головы и шеи высокого риска являются кандидатами для более агрессивной адъювантной химиолучевой терапии (ХЛТ). Важную роль в лечении плоскоклеточного рака головы и шеи отводят таргетной терапии и внутриартериальной регионарной химиотерапии. Выводы: разработка методов лечения больных с местнораспространённым плоскоклеточным раком головы и шеи включает в себя сочетание лучевой терапии (неоадъювантной, адъювантной) с химиотерапией (в качестве радиомодификации, неоадъюватная, адъювантная; таргетная терапия, внутриартериальная химиотерапия) с последующим оперативным лечением, что позволяет улучшить показатели безрецидивного периода, а также трёх-, пятилетней выживаемости.

show abstract

Treatment results of alternating chemoradiotherapy followed by proton beam therapy boost combined with intra-arterial infusion chemotherapy for stage III–IVB tongue cancer

Abstract: PBT-IACT for stage III-IVB tongue cancer has an acceptable toxicity profile and showed good treatment results. This protocol should be considered as a treatment option for locally advanced tongue cancer.

Cited by 33 publications

References 20 publications

Early clinical outcomes of helical tomotherapy/intensity‐modulated proton therapy combination in nasopharynx cancer

Early clinical outcomes of helical tomotherapy/intensity‐modulated proton therapy combination in nasopharynx cancer

Clinical outcomes of retrograde intra-arterial chemotherapy concurrent with radiotherapy for elderly oral squamous cell carcinoma patients aged over 80 years old

Современные Аспекты Лечения Плоскоклеточного Рака Головы И шеи

Contact Info

Product

Resources

About